0
Teva Pharmaceutical Industries has added to its team Mr Gary Buehler, former head of the generics division at the FDA, The Wall Street Journal reported. Mr Buehler joins Teva as vice president of regulatory strategic operations.
- Home
-
Generics
News
- FDA approves generic teriparatide and levetiracetam
- US generics launch and approval for Dr Reddy’s and Lupin
- Five Chinese companies join UN’s MPP for Covid-19 medicines
- South Korean companies to make generic Bridion and COVID-19 drugs
Research
- Japan’s drug shortage crisis: challenges and policy solutions
- Saudi FDA drug approvals and GMP inspections: trend analysis
- Generic medications in the Lebanese community: understanding and public perception
- Community pharmacists’ understanding of generic and biosimilar drugs: Lebanon case study
-
Biosimilars
News
- EMA recommends approval for biosimilar pegfilgrastim Cavoley
- FDA approves first interchangeable ranibizumab biosimilar Ranluspec
- EMA recommends approval for biosimilar Denosumab Ascend and pegfilgrastim Nylaspeg
- FDA approves Ennumo as eighth pegfilgrastim biosimilar
Research
- Biosimilar interchangeability: a necessary fix, but not a silver bullet
- EULAR 2025 RA guidelines streamlined as biosimilar expansion reshapes treatment sequencing
- Biosimilars uptake in Chile: why does it lag behind?
- Biosimilar aflibercept (AVT06) pre-filled syringe promises safer, faster eye injections
- MORE EDITORIAL SECTIONS
- Search
Post your comment